rewirebio.iobenchmarks
Configuration

Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)

Fragment endpoint counts, open chromatin regions, SVM: Feature setting: open chromatin regions.

6 evaluations · 33 results

Overview

An explanatory profile has not yet been reviewed for this record.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

Model Capabilities & Hardware Requirements

Deployment facts recorded for Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024). Fields the record does not carry are marked not recorded.

ParametersNot recorded
Minimum VRAMNot recorded
Inference LatencyNot recorded
Context WindowNot recorded
AccessNot recorded
LicenseNot recorded

Evaluations and results

6 evaluations · 33 results. Different protocols are not a single leaderboard.

Sorted by AUROC (pan-cancer vs healthy; mean of 10 x 10-fold cross-validation) (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.

Tested configurationProtocol and datasetAUROC (pan-cancer vs healthy; mean of 10 x 10-fold cross-validation)AUROC (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)AUROC (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)AUROC (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)AUROC (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)AUROC (liver cancer vs controls; mean of 10 x 10-fold cross-validation)AUROC (liver cancer vs healthy; independent validation)AUROC (lung cancer vs healthy; independent validation)AUROC (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)AUROC (lung cancer vs non-cancer; independent validation)AUROC (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)AUROC (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (liver cancer vs healthy; independent validation)Sensitivity at 85% specificity (lung cancer vs healthy; independent validation)Sensitivity at 85% specificity (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (lung cancer vs non-cancer; independent validation)Sensitivity at 85% specificity (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 85% specificity (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (liver cancer vs healthy; independent validation)Sensitivity at 95% specificity (lung cancer vs healthy; independent validation)Sensitivity at 95% specificity (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (lung cancer vs non-cancer; independent validation)Sensitivity at 95% specificity (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)Sensitivity at 95% specificity (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)
Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)EvaluationHou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2), DELFI 2019 internally cross-validated cancer detection cohort0.964 (best in column)0.9740.9690.9750.963Not reportedNot reportedNot reported0.999Not reported0.9990.8370.9410.8530.8850.927Not reportedNot reported1Not reported10.7170.8620.750.8430.87Not reportedNot reported0.97Not reported0.9730.598
Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)EvaluationHou et al. 2024 pan-cancer vs healthy, Cristiano cohort, 10 x 10-fold cross-validation (Table 1 AUC), DELFI 2019 internally cross-validated cancer detection cohort0.964 (best in column)Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported
Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)EvaluationHou et al. 2024 Jiang cohort cross-validation, liver cancer (Table S2), Jiang et al. 2018 plasma WGS, 90 liver cancer and 135 non-cancer (as used by Hou et al. 2024)Not reportedNot reportedNot reportedNot reportedNot reported0.966Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported
Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)EvaluationHou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3), Mathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024)Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.733Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.504Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.279Not reportedNot reported
Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)EvaluationHou et al. 2024 independent validation, Mathios et al. independent lung cohort (Table S3), Mathios et al. 2021 independent lung cohort, 46 lung cancer and 385 healthy (as used by Hou et al. 2024)Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.83Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.696Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.522Not reportedNot reportedNot reportedNot reported
Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)EvaluationHou et al. 2024 independent validation, Zhou et al. liver cancer cohort (Table S3), Zhou et al. 2022 plasma WGS, 8 liver cancer and 8 healthy (as used by Hou et al. 2024)Not reportedNot reportedNot reportedNot reportedNot reportedNot reported0.922Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.875Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported0.5Not reportedNot reportedNot reportedNot reportedNot reported
All 33 result rows with coverage, uncertainty and sources
Filter evaluations

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configurationProtocol and datasetFindingEvidence and details
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.974 AUROC (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9641 to 0.9834

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C18; group 'BRCA'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.941 Sensitivity at 85% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.9220 to 0.9600

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E18; group 'BRCA'; row 'end'; column 'Sensitivity @85% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.862 Sensitivity at 95% specificity (breast cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.8305 to 0.8942

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D18; group 'BRCA'; row 'end'; column 'Sensitivity @95% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.969 AUROC (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9596 to 0.9788

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C28; group 'CHOL'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.853 Sensitivity at 85% specificity (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.8055 to 0.9012

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E28; group 'CHOL'; row 'end'; column 'Sensitivity @85% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.75 Sensitivity at 95% specificity (cholangiocarcinoma vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.6867 to 0.8133

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D28; group 'CHOL'; row 'end'; column 'Sensitivity @95% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.975 AUROC (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9665 to 0.9837

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C38; group 'CRC'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.885 Sensitivity at 85% specificity (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.8432 to 0.9268

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E38; group 'CRC'; row 'end'; column 'Sensitivity @85% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.843 Sensitivity at 95% specificity (colorectal cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.7956 to 0.8911

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D38; group 'CRC'; row 'end'; column 'Sensitivity @95% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Jiang cohort cross-validation, liver cancer (Table S2)
Dataset: Jiang et al. 2018 plasma WGS, 90 liver cancer and 135 non-cancer (as used by Hou et al. 2024)
0.966 AUROC (liver cancer vs controls; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9580 to 0.9748

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Jiang cohort liver cancer cross-validation

ctdnafrag-20261009-protocol-hou2024-jiang-lihc-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C88; group 'LIHC'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.999 AUROC (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9971 to 1.0000

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C58; group 'NSCLC'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
1 Sensitivity at 85% specificity (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 1.0000 to 1.0000

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E58; group 'NSCLC'; row 'end'; column 'Sensitivity @85% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.97 Sensitivity at 95% specificity (lung cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.9366 to 1.0000

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D58; group 'NSCLC'; row 'end'; column 'Sensitivity @95% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.999 AUROC (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9978 to 0.9997

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C68; group 'OV'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
1 Sensitivity at 85% specificity (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 1.0000 to 1.0000

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E68; group 'OV'; row 'end'; column 'Sensitivity @85% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.973 Sensitivity at 95% specificity (ovarian cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.9533 to 0.9933

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D68; group 'OV'; row 'end'; column 'Sensitivity @95% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.837 AUROC (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.8058 to 0.8680

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C78; group 'PAAD'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.717 Sensitivity at 85% specificity (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.6658 to 0.7675

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E78; group 'PAAD'; row 'end'; column 'Sensitivity @85% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.598 Sensitivity at 95% specificity (pancreatic cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.5398 to 0.6568

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D78; group 'PAAD'; row 'end'; column 'Sensitivity @95% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.964 AUROC (pan-cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9586 to 0.9692

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C8; group 'PANCAN'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.963 AUROC (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)
unitless · higher

Uncertainty: 95% CI 0.9442 to 0.9810

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C48; group 'STAD'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.927 Sensitivity at 85% specificity (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.8959 to 0.9574

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E48; group 'STAD'; row 'end'; column 'Sensitivity @85% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
0.87 Sensitivity at 95% specificity (gastric cancer vs healthy; mean of 10 x 10-fold cross-validation)
fraction · higher

Uncertainty: 95% CI 0.8285 to 0.9115

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), Cristiano cohort cross-validation

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D48; group 'STAD'; row 'end'; column 'Sensitivity @95% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3)
Dataset: Mathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024)
0.733 AUROC (lung cancer vs non-cancer; independent validation)
unitless · higher

Uncertainty: Not reported by the source

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), independent validation on Mathios et al. LUCAS dataset (LUNG)

ctdnafrag-20261009-protocol-hou2024-mathios-lucas-independent

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C18; data set 'Mathios et al. LUCAS dataset (LUNG)'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)Protocol: Hou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3)
Dataset: Mathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024)
0.504 Sensitivity at 85% specificity (lung cancer vs non-cancer; independent validation)
fraction · higher

Uncertainty: Not reported by the source

Coverage: Not reported scored / Not reported eligible

Independent external evaluation · Source checked
Methods, coverage and source

end (open chromatin), independent validation on Mathios et al. LUCAS dataset (LUNG)

ctdnafrag-20261009-protocol-hou2024-mathios-lucas-independent

Aggregation: Not reported

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E18; data set 'Mathios et al. LUCAS dataset (LUNG)'; row 'end'; column 'Sensitivity @85% specificity'

Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.

Use this configuration

How it works, versions and access

Additional methodological details, versions and access terms have not yet been extracted into a structured profile for this configuration. Consult the linked sources and evaluation records below.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

0 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance

No evidence rows match these filters. Choose another scope or clear the search.

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and record identifiers

Technical metadata for this record is tracked under stable ID ctdnafrag-20261009-config-hou2024-fragment-end-count-open-chromatin.

Source locator: Article Table 1 row 'end', column 'open chromatin region'; Experimental Section P29-P41

Related records

How to cite

Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024). Rewire biological model benchmark database, release 2026-11-21-c8bea25e5abb. https://benchmarks.rewirebio.io/database/configuration/ctdnafrag-20261009-config-hou2024-fragment-end-count-open-chromatin/

Release 2026-11-21-c8bea25e5abb. Rankings and values change between releases, so keep the release id in the citation. Cite the original publication as well for any value you reuse: each result links its source.

The compilation and annotations made by Rewire in this release are offered under CC BY 4.0; values and text taken from cited sources stay under the terms of those sources and are not covered by this licence. Data licence

Suggest a correction